GO:0007221 positive regulation of transcription of Notch receptor target: Signaling Pathway, Genes, Functions and Research Methods
Research-grade guide for scientists and biopharma professionals
Key Takeaways
• GO:0007221 describes the activation of transcription of specific genes as a result of Notch signaling, mediated by the Notch intracellular domain (NICD).
• The Notch intracellular domain (NICD) is released by proteolytic cleavage and translocates to the nucleus to form a transcriptional activation complex with CSL (CBF1/RBPJ) and coactivators such as Mastermind-like (MAML).
• This process is essential for cell fate decisions, stem cell maintenance, and tissue homeostasis, and its dysregulation is linked to cancers including non-small-cell lung cancer, liver cancer, and inflammatory breast cancer.
• Key genes involved include NOTCH1, NOTCH3, RBPJ, MAML1, and epigenetic regulators such as Set1 and NCoR1.
• Experimental models for studying GO:0007221 include knockout, point mutation, knock-in, and overexpression cell lines, as well as CRISPR library screening.
• The term is a biological process and is distinct from Notch signaling as a whole; it specifically refers to the transcriptional activation step downstream of NICD nuclear entry.
Description
The Notch signaling pathway is an evolutionarily conserved cell-cell communication system that controls cell fate specification, proliferation, and apoptosis. A critical output of this pathway is the activation of transcription of Notch receptor target genes, a process formally described by the Gene Ontology term GO:0007221 (positive regulation of transcription of Notch receptor target). This term captures the molecular events that convert a Notch receptor-ligand interaction at the cell surface into changes in gene expression in the nucleus, primarily through the release and nuclear function of the Notch intracellular domain (NICD). Understanding this process is fundamental for researchers in developmental biology, stem cell biology, and cancer, because aberrant Notch target gene activation contributes to tumorigenesis and therapy resistance. For example, in non-small-cell lung cancer, a feedback loop involving RFC4 and Notch1 promotes metastasis and stemness, while in liver cancer, SNORA74A drives self-renewal of cancer stem cells through Notch3 signaling. In triple-negative inflammatory breast cancer, Syndecan-1 modulates the cancer stem cell phenotype via Notch and other pathways. These findings underscore the importance of GO:0007221 in both normal physiology and disease. This article provides a research-grade overview of the definition, mechanism, key genes, disease associations, and experimental methods for studying positive regulation of transcription of Notch receptor target, based exclusively on published literature and the QuickGO definition.
positive regulation of transcription of Notch receptor target At A Glance
| GO ID | GO:0007221 |
|---|---|
| GO term | positive regulation of transcription of Notch receptor target |
| Ontology | biological_process |
| Synonym | Notch receptor target transcription factor activation; N receptor target transcription factor activation |
| Major function | Activation of transcription of specific genes in response to Notch signaling, mediated by the Notch intracellular domain (NICD) |
| Key mediator | Notch intracellular domain (NICD) |
| Core transcriptional complex | NICD-CSL (RBPJ)-MAML coactivator complex |
| Associated diseases | Non-small-cell lung cancer, liver cancer, inflammatory breast cancer |
| Research methods | Knockout, point mutation, knock-in, overexpression, CRISPR library screening |
What Is GO:0007221?
GO:0007221, positive regulation of transcription of Notch receptor target, is defined as the activation of transcription of specific genes as a result of Notch signaling, mediated by the Notch intracellular domain. In other words, it is the process by which a signal received by a Notch receptor at the cell membrane leads to increased transcription of target genes in the nucleus, with the Notch intracellular domain (NICD) acting as the key transcriptional coactivator. This term is a biological process and is a child of positive regulation of transcription, but it is specifically restricted to transcriptional activation downstream of Notch signaling.
Why Is positive regulation of transcription of Notch receptor target Important in Cell Biology?
GO:0007221 is important because it represents the final, gene-regulatory step of Notch signaling, a pathway that is essential for metazoan development and tissue homeostasis. Dysregulation of this process is directly implicated in multiple human cancers, where aberrant Notch target gene activation drives cancer stem cell self-renewal, metastasis, and resistance to therapy. For instance, in non-small-cell lung cancer, a RFC4/Notch1 feedback loop promotes metastasis and stemness, and in liver cancer, SNORA74A activates Notch3 signaling to drive self-renewal of cancer stem cells. In inflammatory breast cancer, Syndecan-1 modulates the cancer stem cell phenotype via Notch and other pathways. Therefore, understanding the molecular mechanisms of GO:0007221 is critical for identifying therapeutic targets and developing strategies to modulate Notch-driven transcription in disease.
• Controls cell fate decisions during development and in adult stem cell niches.
• Drives cancer stem cell self-renewal and tumor progression in liver cancer.
• Promotes metastasis and stemness in non-small-cell lung cancer through RFC4/Notch1 feedback.
• Modulates the cancer stem cell phenotype in triple-negative inflammatory breast cancer.
• Is regulated by epigenetic factors such as Set1, which promotes Notch-induced transcriptional activation.
• Is limited by corepressor NCoR1, which alters Notch signaling and angiogenic capacity.
• Represents a therapeutic target for cancers with aberrant Notch activation.
• Can be studied using CRISPR-based knockout, knock-in, and overexpression models.
• Involved in calorie restriction-induced gastric Notch-FOXO1 pathway expanding ghrelin cells.
• Provides a paradigm for understanding how extracellular signals are converted into transcriptional programs.
What Happens During positive regulation of transcription of Notch receptor target?
Ligand binding and receptor activation
In simple terms: A signal from a neighboring cell binds to the Notch receptor, turning it on.
The process begins when a Notch receptor on the surface of a signal-receiving cell binds to a ligand (e.g., Delta-like or Jagged) presented by a neighboring cell. This interaction triggers a conformational change in the Notch receptor, exposing a cleavage site for ADAM metalloproteases. This step is the initial event that ultimately leads to transcriptional activation of Notch target genes, as defined by GO:0007221.
Proteolytic cleavage and release of NICD
In simple terms: The Notch receptor is cut, releasing a piece that travels to the nucleus.
Following ligand binding and ADAM-mediated cleavage, the Notch receptor undergoes intramembrane proteolysis by the gamma-secretase complex, releasing the Notch intracellular domain (NICD) from the membrane. NICD is the key mediator of GO:0007221, as it translocates to the nucleus to directly participate in transcriptional activation. This cleavage event is a point of regulation and is targeted by gamma-secretase inhibitors in research and therapy.
Nuclear translocation and complex assembly
In simple terms: The released piece enters the nucleus and teams up with other proteins to turn on genes.
Once released, NICD translocates into the nucleus, where it binds to the DNA-binding protein CSL (also known as RBPJ or CBF1). This interaction converts CSL from a transcriptional repressor into an activator by recruiting coactivators such as Mastermind-like (MAML) proteins and histone acetyltransferases. The formation of this NICD-CSL-MAML complex is a hallmark of positive regulation of transcription of Notch receptor target (GO:0007221). Recent work has shown that the histone methyltransferase Set1 promotes Notch-induced transcriptional activation, further linking chromatin modification to this process.
Transcriptional activation of target genes
In simple terms: The protein complex turns on specific genes, leading to changes in cell behavior.
The NICD-CSL-MAML complex recruits additional coactivators and chromatin-modifying enzymes to the promoters and enhancers of Notch target genes, leading to increased transcription. Target genes include HES and HEY family members, which in turn regulate downstream effectors of cell fate, proliferation, and stemness. This transcriptional output is the defining outcome of GO:0007221. In cancer, aberrant activation of this step drives expression of genes that promote metastasis and stem cell properties, as seen in non-small-cell lung cancer and liver cancer.
Negative regulation and feedback
In simple terms: The process can be dampened by corepressors and feedback loops to avoid overactivation.
Positive regulation of transcription of Notch receptor target is balanced by negative regulators. For example, NCoR1 limits angiogenic capacity by altering Notch signaling, acting as a corepressor that restrains excessive transcriptional activation. Additionally, feedback loops such as the RFC4/Notch1 loop in non-small-cell lung cancer can sustain or amplify Notch target gene expression, contributing to metastasis and stemness. Understanding these regulatory mechanisms is essential for designing interventions that modulate GO:0007221 in disease contexts.
Key Genes Involved in GO:0007221 positive regulation of transcription of Notch receptor target
The following genes and proteins are central to the positive regulation of transcription of Notch receptor target (GO:0007221), based on published literature.
| Gene | Major Role | Research Relevance |
|---|---|---|
| NOTCH1 | Notch receptor; ligand binding triggers NICD release and target gene activation | Mutations and overexpression linked to NSCLC metastasis and stemness |
| NOTCH3 | Notch receptor; activation drives self-renewal of liver cancer stem cells | Target for hepatocellular carcinoma research |
| RBPJ (CSL/CBF1) | DNA-binding transcription factor that recruits NICD to target gene promoters | Core component of the Notch transcriptional complex |
| MAML1 | Transcriptional coactivator that binds NICD-CSL complex | Essential for Notch target gene activation |
| Set1 | Histone methyltransferase that promotes Notch-induced transcriptional activation | Epigenetic regulator of GO:0007221 |
| NCoR1 | Corepressor that limits Notch signaling and angiogenic capacity | Negative regulator of Notch target transcription |
| RFC4 | Part of RFC complex; forms feedback loop with Notch1 to promote NSCLC metastasis | Potential therapeutic target in lung cancer |
| SNORA74A | Small nucleolar RNA that drives liver cancer stem cell self-renewal via Notch3 | Oncogenic regulator of Notch3 signaling |
| Syndecan-1 | Cell surface proteoglycan that modulates cancer stem cell phenotype via Notch | Marker and therapeutic target in inflammatory breast cancer |
| EGFR | Receptor tyrosine kinase that crosstalks with Notch signaling | Cancer stem cell biomarker in EGFR-mutant NSCLC |
| IL-6/STAT3 | Inflammatory pathway that interacts with Notch to modulate stemness | Therapeutic target in inflammatory breast cancer |
| FOXO1 | Transcription factor activated by calorie restriction in gastric Notch pathway | Regulator of ghrelin cell expansion |
| REG4 | Promotes proliferation and anti-apoptosis in cancer, potentially via Notch | Biomarker in gastrointestinal cancers |
| HES1 | Canonical Notch target gene; transcriptional repressor | Readout of Notch transcriptional activation |
| HEY1 | Canonical Notch target gene; involved in cell fate decisions | Marker of Notch pathway activity |
| NOTCH2 | Notch receptor paralog with context-dependent roles | Potential target in cancers and developmental disorders |
| NOTCH4 | Notch receptor paralog implicated in breast cancer | Associated with cancer stem cell phenotype |
| JAG1 | Notch ligand that activates Notch receptors on neighboring cells | Modulates Notch signaling in development and cancer |
How Is positive regulation of transcription of Notch receptor target Regulated?
The positive regulation of transcription of Notch receptor target (GO:0007221) is tightly regulated at multiple levels. Extracellularly, ligand availability and receptor glycosylation modulate Notch activation. Intracellularly, proteolytic cleavage by ADAM and gamma-secretase is a key control point. In the nucleus, the balance between coactivators (e.g., MAML1, Set1) and corepressors (e.g., NCoR1) determines the transcriptional output. Additionally, feedback loops such as the RFC4/Notch1 loop can sustain Notch target gene expression in cancer. Metabolic and stress signals, such as calorie restriction, can also influence Notch-FOXO1 pathways in specific tissues. These regulatory mechanisms ensure that Notch target gene activation is context-dependent and reversible, and their dysregulation contributes to disease.
positive regulation of transcription of Notch receptor target and Human Disease
| Gene | Disease / Biology | Potential Experimental Model |
|---|---|---|
| NOTCH1 | Non-small-cell lung cancer metastasis and stemness | Knockout and overexpression in NSCLC cell lines |
| NOTCH3 | Liver cancer stem cell self-renewal and hepatocarcinogenesis | Knockdown or knockout in liver cancer cell lines |
| Syndecan-1 | Triple-negative inflammatory breast cancer | Knockout in breast cancer cell lines |
| NCoR1 | Angiogenesis regulation | Endothelial cell knockout models |
| FOXO1 | Calorie restriction-induced ghrelin cell expansion | Knockout mouse models |
Notch target transcription in non-small-cell lung cancer
In non-small-cell lung cancer (NSCLC), a feedback loop between RFC4 and Notch1 promotes metastasis and stemness. Activation of Notch target genes, a direct consequence of GO:0007221, contributes to the cancer stem cell phenotype and resistance to therapy. Additionally, cancer stem cell biomarkers in EGFR-mutation-positive NSCLC are linked to Notch and other signaling pathways. Targeting the transcriptional activation step of Notch signaling may offer therapeutic benefits in NSCLC.
Notch3-driven liver cancer stem cell self-renewal
In hepatocellular carcinoma, SNORA74A drives self-renewal of liver cancer stem cells and hepatocarcinogenesis through activation of Notch3 signaling. This involves the positive regulation of transcription of Notch receptor target genes, which sustains the stem cell pool and promotes tumor growth. Inhibiting Notch3-mediated transcription could be a strategy to target liver cancer stem cells.
Notch signaling in inflammatory breast cancer
Syndecan-1 is a novel molecular marker for triple-negative inflammatory breast cancer and modulates the cancer stem cell phenotype via IL-6/STAT3, Notch, and EGFR signaling pathways. The activation of Notch target genes (GO:0007221) is part of this network, contributing to the aggressive phenotype. Targeting Notch transcriptional activation may help overcome therapy resistance in this subtype.
Notch signaling in metabolic and angiogenic regulation
Calorie restriction activates a gastric Notch-FOXO1 pathway to expand ghrelin cells, demonstrating a role for Notch target gene activation in metabolic regulation. In angiogenesis, NCoR1 limits angiogenic capacity by altering Notch signaling, highlighting the importance of negative regulation of GO:0007221. These findings link Notch transcriptional activation to broader physiological processes beyond cancer.
From positive regulation of transcription of Notch receptor target-Related Genes to Experimental Models
| Research Question | Suitable Model |
|---|---|
| Does loss of NOTCH1 affect target gene transcription and metastasis? | NOTCH1 knockout cell line (e.g., NSCLC) |
| Does a point mutation in RBPJ disrupt NICD binding? | RBPJ point-mutation knock-in cell line |
| Can we tag NICD to track its nuclear localization? | Tagged knock-in of NOTCH1 with fluorescent protein |
| Does overexpression of SNORA74A activate Notch3 target genes? | SNORA74A overexpression in liver cancer cells |
| Which genes are essential for Notch target transcription? | CRISPR library screening in Notch-dependent cells |
| Does NCoR1 knockout alter angiogenic capacity? | NCoR1 knockout endothelial cells |
How to Study the positive regulation of transcription of Notch receptor target Process
| Method | What It Measures | Typical Application |
|---|---|---|
| RNA-seq | Changes in Notch target gene expression | Identifying transcriptional output of GO:0007221 |
| ChIP-seq | Binding of NICD/CSL/MAML to chromatin | Mapping direct Notch target genes |
| Luciferase reporter assay | Notch transcriptional activity | Screening for modulators of GO:0007221 |
| Live-cell imaging | Nuclear translocation of NICD | Dynamic studies of Notch activation |
| Proteomics | Protein interactions and modifications | Identifying coactivators/corepressors |
| CRISPR knockout | Loss-of-function effects on target genes | Validating gene function in GO:0007221 |
| CRISPR knock-in | Tagged protein expression | Tracking NICD localization |
| CRISPR library screening | Genome-wide identification of regulators | Discovering novel modulators of Notch transcription |
Transcriptional profiling by RNA-seq
RNA sequencing (RNA-seq) is widely used to measure changes in Notch target gene expression upon modulation of GO:0007221. For example, RNA-seq can identify genes whose transcription is activated by NICD in cancer cells. This method provides a global view of the transcriptional output and can reveal feedback loops and off-target effects.
Chromatin immunoprecipitation (ChIP) and ChIP-seq
ChIP and ChIP-seq are used to detect binding of NICD, CSL (RBPJ), MAML1, and chromatin modifiers to Notch target gene promoters and enhancers. These methods help define the direct targets of the Notch transcriptional complex and the epigenetic changes associated with activation. They are essential for confirming that a gene is regulated by GO:0007221.
Reporter assays and live-cell imaging
Notch-responsive luciferase reporters and fluorescent reporters can monitor the activity of GO:0007221 in real time. Live-cell imaging of tagged NICD allows tracking of its nuclear translocation and complex assembly. These approaches are useful for dynamic studies of Notch activation in response to ligands or drugs.
Proteomics and interactomics
Mass spectrometry-based proteomics can identify components of the NICD transcriptional complex and their post-translational modifications. Interactomics studies have revealed coactivators such as MAML1 and Set1, as well as corepressors like NCoR1. These methods provide a comprehensive view of the molecular machinery underlying GO:0007221.
How CRISPR Can Be Used to Study GO:0007221 positive regulation of transcription of Notch receptor target
Knockout
CRISPR knockout is used to delete genes involved in GO:0007221, such as NOTCH1, NOTCH3, RBPJ, or MAML1, to assess their requirement for Notch target gene transcription. For example, NOTCH1 knockout in NSCLC cells reduces metastasis and stemness, and NOTCH3 knockout in liver cancer cells impairs self-renewal. Knockout models are essential for establishing causality in the pathway.
Point Mutation
Point mutations can be introduced into genes encoding components of the Notch transcriptional complex to dissect specific residues required for interaction or activity. For instance, mutating the NICD binding interface of RBPJ can disrupt complex formation and target gene activation. Such models help distinguish between different functions of a protein and validate structural insights.
Knock-in
Knock-in of tagged versions of NICD, RBPJ, or MAML1 allows visualization and purification of the transcriptional complex. Fluorescent tags enable live-cell imaging of nuclear translocation, while affinity tags facilitate proteomic analysis. Knock-in models are also used to introduce disease-associated mutations for functional studies.
Overexpression
Overexpression of Notch receptors, ligands, or downstream effectors such as SNORA74A can activate GO:0007221 and drive cancer stem cell phenotypes. For example, SNORA74A overexpression in liver cancer cells activates Notch3 signaling and promotes self-renewal. Overexpression models are useful for gain-of-function studies and for testing therapeutic inhibitors.
How EDITGENE Supports positive regulation of transcription of Notch receptor target Research
Researchers studying positive regulation of transcription of Notch receptor target-related genes often need to determine whether a candidate gene is causally involved in Notch target gene activation, and to dissect the molecular mechanisms with precision. EDITGENE provides a comprehensive suite of CRISPR-based services to support such investigations, from gene knockout to point mutation, knock-in, overexpression, and high-throughput library screening, all tailored to the needs of Notch signaling research.
Contact EDITGENE today to design your custom CRISPR model for positive regulation of transcription of Notch receptor target research.
Frequently Asked Questions About positive regulation of transcription of Notch receptor target
What is GO:0007221?
GO:0007221 is the Gene Ontology term for positive regulation of transcription of Notch receptor target, defined as the activation of transcription of specific genes as a result of Notch signaling, mediated by the Notch intracellular domain.
What genes are involved in positive regulation of transcription of Notch receptor target?
Key genes include NOTCH1, NOTCH3, RBPJ (CSL), MAML1, Set1, NCoR1, RFC4, SNORA74A, and Syndecan-1, among others.
How does Notch signaling activate transcription?
Ligand binding triggers proteolytic cleavage of the Notch receptor, releasing the Notch intracellular domain (NICD), which translocates to the nucleus, binds CSL/RBPJ, and recruits coactivators such as MAML1 to activate target gene transcription.
What diseases are associated with GO:0007221?
Dysregulation of this process is linked to non-small-cell lung cancer, liver cancer, inflammatory breast cancer, and angiogenesis-related disorders.
What are the research methods to study GO:0007221?
Common methods include RNA-seq, ChIP-seq, luciferase reporter assays, live-cell imaging, proteomics, and CRISPR-based knockout, knock-in, and overexpression models.
How is Notch target gene transcription regulated?
It is regulated by ligand availability, proteolytic cleavage, nuclear complex assembly, and the balance between coactivators (e.g., MAML1, Set1) and corepressors (e.g., NCoR1), as well as feedback loops.
What is the role of NICD in GO:0007221?
The Notch intracellular domain (NICD) is the key mediator; it is released from the membrane, enters the nucleus, and forms a transcriptional activation complex with CSL and MAML proteins.
Can CRISPR be used to study Notch target transcription?
Yes, CRISPR knockout, point mutation, knock-in, and overexpression models are widely used to dissect the function of genes involved in GO:0007221.
What are canonical Notch target genes?
Canonical target genes include HES1 and HEY1, which are transcriptionally activated by the NICD-CSL-MAML complex.
How does NCoR1 affect Notch signaling?
NCoR1 acts as a corepressor that limits Notch signaling and angiogenic capacity, thereby negatively regulating the transcription of Notch target genes.
Conclusion
GO:0007221, positive regulation of transcription of Notch receptor target, is a central biological process that converts Notch receptor activation into changes in gene expression. It is mediated by the Notch intracellular domain (NICD) and a core transcriptional complex including CSL/RBPJ and MAML proteins. Dysregulation of this process contributes to cancer stem cell phenotypes, metastasis, and other pathologies, making it a key area of research. Advances in CRISPR-based models and high-throughput methods continue to unravel the molecular details and regulatory networks of this process. Understanding GO:0007221 not only illuminates fundamental cell signaling but also offers opportunities for therapeutic intervention in Notch-driven diseases.
References
- 1. Codony-Servat J et al.. 2019. Cancer Stem Cell Biomarkers in EGFR-Mutation-Positive Non-Small-Cell Lung Cancer.. Clin Lung Cancer 20(3):167-177 PMID: 30885551
- 2. McKimpson WM et al.. 2024. Calorie restriction activates a gastric Notch-FOXO1 pathway to expand ghrelin cells.. J Cell Biol 223(10) PMID: 38958606
- 3. Liu L et al.. 2021. An RFC4/Notch1 signaling feedback loop promotes NSCLC metastasis and stemness.. Nat Commun 12(1):2693 PMID: 33976158
- 4. Zheng HC et al.. 2022. REG4 promotes the proliferation and anti-apoptosis of cancer.. Front Cell Dev Biol 10:1012193 PMID: 36172286
- 5. Ibrahim SA et al.. 2017. Syndecan-1 is a novel molecular marker for triple negative inflammatory breast cancer and modulates the cancer stem cell phenotype via the IL-6/STAT3, Notch and EGFR signaling pathways.. Mol Cancer 16(1):57 PMID: 28270211
- 6. Liu H et al.. 2026. Set1 promotes Notch-induced transcriptional activation.. Cell Mol Life Sci 83(1) PMID: 41843107
- 7. Zhou Z et al.. 2025. SNORA74A Drives Self-Renewal of Liver Cancer Stem Cells and Hepatocarcinogenesis Through Activation of Notch3 Signaling.. Adv Sci (Weinh) 12(26):e2504054 PMID: 40270470
- 8. Teichmann T et al.. 2024. NCoR1 limits angiogenic capacity by altering Notch signaling.. J Mol Cell Cardiol 188:65-78 PMID: 38359551
